Understanding Anatomical Patterns in Refractory Psoriatic Lesions

Biologic therapies have dramatically improved outcomes for patients with moderate-to-severe psoriasis vulgaris and psoriatic arthritis. However, clinicians frequently encounter persistent cutaneous plaques, commonly termed refractory psoriatic lesions, that fail to clear completely despite systemic therapy. Cutaneous psoriasis exhibits substantial anatomical heterogeneity, meaning that plaques in specific body regions respond differently to targeted immune inhibition. For instance, while biologics rapidly clear trunk and back lesions, peripheral sites often demonstrate persistent inflammation. Therefore, understanding regional susceptibility is essential for managing clinician and patient expectations. When systemic medications only achieve partial clearance, patients experience significant physical discomfort, functional impairment, and emotional distress. Furthermore, distinct anatomical areas possess unique microenvironments, including variable vascular networks, mechanical friction, and stratum corneum thickness. Consequently, pathogenic tissue resident memory T cells can persist within these protected sanctuary sites despite continuous biologic administration. Clinicians must identify which anatomical locations require targeted adjunctive care rather than assuming total biologic failure. In addition, tracking regional responsiveness allows dermatologists and rheumatologists to formulate individualized treatment strategies that optimize patient adherence and prevent unnecessary therapy abandonment.

Evaluating the Biologic Switching Study Design and Cohort

To investigate persistent regional plaques, a retrospective study evaluated real-world patient records from Jichi Medical University Hospital. The investigators reviewed 71 biologic-switching episodes among 50 patients treated between January 2010 and December 2019. Because several patients required multiple drug transitions over time, they contributed more than one switching episode to the analysis. The researchers methodically assessed 13 anatomical regions at the baseline transition and at the final follow-up. Furthermore, the team defined improvement as the complete disappearance of a lesion that was explicitly present before switching. In contrast, body regions documented as clear prior to switching were classified as non-improved to prevent analytical skewing. In addition, regions lacking documentation regarding baseline status were entirely excluded from the statistical model. To account for within-patient correlation across multiple anatomical zones, researchers applied a logistic generalized linear mixed-effects model. Consequently, this rigorous statistical approach ensured that the findings accurately reflected true regional drug effects rather than random observational variation. The resulting data provide dependable real-world clarity regarding therapeutic switching dynamics in routine clinical dermatology practice.

Predominant Anatomical Sites of Refractory Psoriatic Lesions

The study demonstrated consistent anatomical distributions of persistent disease across both disease cohorts before and after biologic switching. Specifically, the lower extremities emerged as the single most common site harboring refractory psoriatic lesions in both groups. Among patients with psoriasis vulgaris, the upper extremities represented the second most frequent anatomical location of stubborn plaques. Conversely, patients diagnosed with psoriatic arthritis exhibited notable recalcitrance on the scalp following lower limb involvement. Importantly, the overall distribution of refractory regions remained broadly similar before and after switching biologics. Therefore, switching to an alternative biologic agent did not alter the fundamental anatomical predisposition of persistent plaques. These findings indicate that local tissue biology heavily dictates cutaneous clearance, independent of systemic therapeutic mechanism. For example, lower limb skin experiences continuous hydrostatic pressure, venous stasis, and regular biomechanical tension. Consequently, these localized environmental stressors sustain cellular inflammation and promote plaque recalcitrance despite targeted cytokine blockade. Clinicians should recognize that persistent lower leg plaques reflect anatomical vulnerability rather than complete therapeutic inefficacy.

Comparative Clearance in Oral Versus Biologic Transitions

A crucial outcome of the investigation involved comparing lesion resolution between different therapeutic switching pathways. Patients transitioning from conventional oral systemic medications to biologics experienced significantly greater odds of documented lesion improvement. In fact, the oral-to-biologic switching group demonstrated an odds ratio of 2.12 compared to the biologic-to-biologic group. This significant difference highlights the heightened responsiveness typically observed in biologic-naive cutaneous tissue. When patients initiate their first biologic therapy, their inflammatory pathways generally lack prior exposure to targeted cytokine neutralization. In contrast, patients undergoing biologic-to-biologic transitions frequently exhibit established refractory phenotypes, secondary loss of response, or neutralizing antidrug antibodies. Furthermore, long-standing disease treated with multiple biologics often undergoes immunologic reprogramming toward alternative inflammatory cascades. Therefore, clinicians must maintain grounded expectations when switching biologics in heavily pretreated individuals. While rotating biologics remains a cornerstone strategy for maintaining systemic control, achieving complete regional clearance becomes progressively more challenging. As a result, managing recalcitrant areas in biologic-experienced patients frequently requires integrated multi-targeted treatment regimens.

Clinical Implications and Targeted Management in Practice

These findings offer essential guidance for clinicians managing psoriasis and psoriatic arthritis, particularly in diverse real-world settings like India. In resource-conscious healthcare environments, patients often undergo extensive treatment with conventional oral drugs before accessing biologics. Consequently, when clinicians finally initiate biologic therapy, these biologic-naive patients achieve superior odds of clearing stubborn plaques. However, when secondary failure forces a biologic switch, persistent lower extremity lesions present major management hurdles. Regional factors, such as warm climates, occupational standing, and friction, exacerbate localized skin inflammation and induce Koebnerization. Therefore, clinicians should avoid premature biologic switching if joint symptoms and overall body surface area remain well controlled. Instead, practitioners should intensify targeted local therapies, such as superpotent topical corticosteroids, vitamin D analogues, and keratolytics like salicylic acid. In addition, localized phototherapy and gentle skin care practices significantly improve stubborn lower limb and scalp disease. Ultimately, combining systemic biologic therapy with diligent topical regimens provides a cost-effective, durable approach to recalcitrant disease without sacrificing systemic disease control.

Frequently Asked Questions

Which anatomical sites are most prone to refractory psoriatic lesions?

The lower extremities represent the most common site of persistent disease in both psoriasis vulgaris and psoriatic arthritis. In addition, the upper extremities frequently show resistance in plaque psoriasis, whereas the scalp remains particularly stubborn in psoriatic arthritis. These areas experience constant mechanical friction, elevated hydrostatic pressure, and distinct microvascular conditions that sustain localized inflammation and impede complete therapeutic clearance despite systemic cytokine inhibition.

Why does switching from oral therapy yield better lesion clearance than biologic switching?

Patients transitioning from conventional oral drugs to biologics are usually biologic-naive, meaning their immune system has not developed resistance to targeted cytokine blockade. In contrast, patients who require biologic-to-biologic switching frequently exhibit refractory disease pathways, potential antidrug antibodies, or immunologic escape mechanisms. Consequently, biologic-naive patients experience significantly higher odds of clearing stubborn anatomical lesions than individuals who have already failed one or more biologic therapies.

How should clinicians approach persistent lesions on the lower extremities?

When a biologic successfully manages systemic arthritis and overall body surface area, clinicians should maintain the systemic agent. Instead of switching biologics immediately, practitioners should intensify targeted local therapies. Combining superpotent topical corticosteroids with vitamin D analogues, keratolytic agents like salicylic acid, and localized phototherapy effectively clears stubborn plaques. Furthermore, addressing venous stasis and reducing local friction helps suppress localized inflammation on the lower legs.

Disclaimer: This content is for informational and educational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Healthcare professionals must exercise independent clinical judgment when interpreting these findings. Refer to the latest local and national guidelines for clinical practice.

References

1. Ando T et al. Refractory Psoriatic Lesions in Japanese Patients Before and After Switching Biologics. J Dermatol. 2026 Oct 14. doi: 10.1111/1346-8138.70532. PMID: 42875367.


2. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.


3. Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71(1):5-32.